Cancer immunotherapy: the art of targeting the tumor immune microenvironment

被引:0
作者
Jesse Lopes da Silva
Alexssandra Lima S. Dos Santos
Natalia Cristina Cardoso Nunes
Flora de Moraes Lino da Silva
Carlos Gil Moreira Ferreira
Andreia Cristina de Melo
机构
[1] Brazilian National Cancer Institute (INCA),Clinic Oncomed
[2] Oncoclinicas Institute for Research and Education,undefined
[3] Oncomed Clinic Oncologica,undefined
来源
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词
Immunotherapy; Immune microenvironment; Adoptive cell therapy; Therapeutic vaccines; Immune checkpoints inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
For many decades, cancer treatment has been strongly directed toward the development of cytotoxic and cytostatic drugs, quite often leading to disappointing results due to the inter- and intra-tumoral heterogeneity. Lately, this intra-cellular look has given way to the understanding of the tumor microenvironment, thus enabling modification of the immunological dynamics between tumor cells and their host. An era of new drugs aiming to unlock the host immune system against tumor cells is steadily increasing. Strategies involving adoptive cell therapy, therapeutic vaccines, immune checkpoint inhibitors and so on have provided spectacular clinical responses and increased survival in previously refractory settings and “hard-to-treat” cancers. Based on a comprehensive search in the main scientific databases, annals of recent renowned oncology congresses and platforms of ongoing trials, the clinical pharmacology characteristics of the main classes of immunotherapeutic agents, as well as the new treatment strategies related to immunotherapy in solid tumors, are carefully discussed throughout this review.
引用
收藏
页码:227 / 240
页数:13
相关论文
共 286 条
[1]  
Kamta J(2017)Advancing cancer therapy with present and emerging immuno-oncology approaches Front Oncol 7 64-248
[2]  
Chaar M(2016)Development of new immunotherapy treatments in different cancer types J Med Life 9 240-1781
[3]  
Ande A(2018)Current status and future directions of cancer immunotherapy J Cancer 9 1773-1570
[4]  
Altomare DA(2011)Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion Science 331 1565-727
[5]  
Ait-Oudhia S(2006)Cancer despite immunosurveillance: immunoselection and immunosubversion Nat Rev Immunol 6 715-1111
[6]  
Stanculeanu DL(2017)Neoantigen targeting—dawn of a new era in cancer immunotherapy? Front Immunol 410 1107-674
[7]  
Daniela Z(2001)IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 144 646-2225
[8]  
Lazescu A(2011)Hallmarks of cancer: the next generation Cell 191 2217-204
[9]  
Bunghez R(2013)Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy J Immunol Baltim Md 1950 37 193-369
[10]  
Anghel R(2017)Adoptive T-cell therapy for solid tumors Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 150 361-4557